Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822552 | 0.90 | ADORA1 (0.40) | BRD4ADORA1KHKADORA2A | |
| SCHEMBL6822496 | 0.88 | ADORA1 (0.42) | BRD4ADORA1KHKDRD2ADORA2A | |
| SCHEMBL6822588 | 0.86 | ADORA1 (0.41) | ADORA1ALDH1A1USP2LMNAHSD17B10 | |
| SCHEMBL6822056 | 0.86 | KHK (0.43) | ADORA1LMNAKHKDRD2 | |
| SCHEMBL6822109 | 0.86 | ADORA1 (0.41) | BRD4ADORA1ALDH1A1KDM4ELMNA | |
| SCHEMBL6822350 | 0.85 | ADORA1 (0.40) | BRD4ADORA1USP2LMNAHSD17B10 | |
| SCHEMBL6822057 | 0.85 | ADORA1 (0.41) | ADORA1USP2HSD17B10 | |
| SCHEMBL6822080 | 0.85 | ADORA1 (0.37) | ADORA1ALDH1A1USP2HSD17B10KHK | |
| SCHEMBL6821993 | 0.84 | KHK (0.41) | ADORA1ALDH1A1KDM4ELMNAHSD17B10 | |
| SCHEMBL6822097 | 0.84 | ADORA1 (0.39) | BRD4ADORA1ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | BRD4 2847/4885ADORA1 22/4885ALDH1A1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.